Apomorphine increases blood glucose concentrations in Parkinson's disease.
Data from studies indicate that blood glucose levels may be influenced by stimulation of central D1 and D2 dopamine receptors. This is modulated by central dopamine receptor status. We studied apomorphine-induced increase in blood glucose levels in Parkinson's disease compared with those in Parkinsonian syndromes unresponsive to dopaminergic drugs. Results indicate that apomorphine-induced blood glucose level increases are significant only in Parkinson's disease. As in the animal, this could possibly be explained by central dopamine receptor status.
Tison
F
F
Service de Neurologie, Hôpital Pellegrin, Bordeaux, France.
Fouillet
N
N
Henry
P
P
D000368:Aged; D001058:Apomorphine / Q000009:adverse effects* / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism*; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D010300:Parkinson Disease / Q000097:blood* / Q000188:drug therapy; D010302:Parkinson Disease, Secondary / Q000188:drug therapy
D001786:Blood Glucose; D007980:Levodopa; D001058:Apomorphine